Abstract
A variety of angiogenic factors have been identified in choroidal neovascularization (CNV) membranes of patients with exudative age-related macular degeneration (AMD) (1), and several different angiogenic factors can cause experimental CNV (2,3). One of the rate-limiting steps for neovascularization is the angiogenic factor-induced activation of vascular endothelial cells and induction of the angiogenic proteolytic cascade, which allows the endothelial cells to break through the vessel wall and migrate through interstitial tissue to form new blood vessels. An ideal therapeutic agent for the treatment of exudative AMD should be able to inhibit CNV independent of the factor(s) inducing neovascularization and should attack the rate-limiting step of neovascularization. In addition, this agent should be locally administered via a mechanism that does not pierce the eye, deliver the therapeutic agent to the macula, and not require frequent administration. Due to the chronic nature of AMD, the therapeutic agent should have superior ocular and systemic safety.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44;3186–3193.
Cui JZ, Kimura H, Spee C, et al. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol 2000;238;326–333.
Kimura H, Sakamoto T, Hinton DR, et al. A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci 1995;36;2110–2119.
Clark AF, Morrison JC. Corticosteroid glaucoma. In: Glaucoma: Science and Practice. Morrison JC, Pollack IP, eds. Thieme Medical Publishers, New York: 2002.
Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11;478–483.
McNatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 1999;15;413–423.
BenEzra D, Griffin BW, Maftzir G, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997;38;1954–1962.
Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs 1997;6;1867–1877.
Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42;283–290.
Bingaman DP, Liu C, Landers RA, Gu X. Local delivery of anecortave acetate inhibits laser-induced choroidal neovascularization (CNV) in the mouse. ARVO Annual Meeting. Fort Lauderdale, FL, 2004.
Clark AF, Mellon J, Li XY, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999;40;2158–2162.
Murray TG, Escalona-Benz E, Hayden BC, et al. Subconjunctival anecortave acetate, an angiostatic steroid, in the treatment of a murine model of retinoblastoma. ARVO Annual Meeting. Fort Lauderdale, FL, 2003.
Murray TG. Combined anti-angiogenic and peri-ocular chemotherapy using anecortave acetate and carboplatin in the treatment of retinal tumors in the LHbetaTag murine transgenic model of retinoblastoma. ARVO Annual Meeting. Fort Lauderdale, FL, 2004.
Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230;1375–1378.
Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci 2003;8;d1030–d1033.
Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994;36;724–731.
Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003;2(4 Suppl 1):S127–S133.
DeFaller JM, Clark AF. A new pharmacological treatment for angiogenesis. In: Pterygium. Taylor HR, ed. Kugler Publications, The Hague: 2000.
Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003;22;721–748.
Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol 1997;124;521–529.
Smith RE, Nozik RA. In Uveitis: A Clinical Approach to Diagnosis and Management, 2nd Edition. Williams and Wilkins Publishers, Baltimore: 1989;51-76.
Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol 1987;103(3 Pt 1):281–288.
D’Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110;2372–2383; discussion 2384, 2385.
D’Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23;14–23.
Yaacobi Y, Chastain J, Lowseth L, et al. In-vivo studies with trans-scleral anecortave acetate delivery device designed to treat choroidal neovascularization in AMD. ARVO Annual Meeting. Fort Lauderdale, FL, 2003.
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110;979–986.
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22;143–152.
Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120;338–346.
Wheeler GD. Ruboxistaurin (Eli Lilly). IDrugs 2003;6;159–163.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Robertson, S.M., Davis, A.A., Dahlin, D.C., Clark, A.F. (2006). Anecortave Acetate. In: Tombrain-Tink, J., Barnstable, C.J. (eds) Ocular Angiogenesis. Opthalmology Research. Humana Press. https://doi.org/10.1007/978-1-59745-047-8_19
Download citation
DOI: https://doi.org/10.1007/978-1-59745-047-8_19
Publisher Name: Humana Press
Print ISBN: 978-1-58829-514-9
Online ISBN: 978-1-59745-047-8
eBook Packages: MedicineMedicine (R0)